Ipam

Leaflet attached to the packaging: patient information

IPAM, 5 mg + 1.25 mg + 5 mg, film-coated tablets

IPAM, 5 mg + 1.25 mg + 10 mg, film-coated tablets

IPAM, 10 mg + 2.5 mg + 5 mg, film-coated tablets

IPAM, 10 mg + 2.5 mg + 10 mg, film-coated tablets

Perindopril arginine + Indapamide + Amlodipine

Read the leaflet carefully before taking the medicine, as it contains important information for the patient.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, including those not listed in this leaflet, please inform your doctor or pharmacist. See section 4.

Table of contents of the leaflet:

• 1. What is IPAM and what is it used for
• 2. Important information before taking IPAM
• 3. How to take IPAM
• 4. Possible side effects
• 5. How to store IPAM
• 6. Contents of the pack and other information

1. What is IPAM and what is it used for

IPAM is a combination product containing three active substances: perindopril, indapamide, and amlodipine.
This is a blood pressure lowering medicine used to treat high blood pressure (hypertension).
Patients already taking perindopril and indapamide in one medicine and amlodipine in another can take one IPAM tablet instead, which contains these three active substances in the same doses.
Each active substance lowers blood pressure, and together they help control blood pressure in the patient:

• perindopril belongs to a group of medicines called angiotensin-converting enzyme inhibitors (ACE inhibitors). It works by widening the blood vessels, making it easier for the heart to pump blood.
• indapamide is a diuretic (a type of medicine that increases urine production) belonging to the group of sulfonamide derivatives with an indole ring. Diuretics increase the amount of urine produced by the kidneys. However, indapamide differs from other diuretics in that it causes only a slight increase in urine production.
• amlodipine is a calcium channel blocker (belonging to the group of medicines called dihydropyridines). It causes relaxation of the blood vessels, making it easier for blood to flow through them.

2. Important information before taking IPAM

When not to take IPAM:

• if the patient is allergic to perindopril or other ACE inhibitors, indapamide or other sulfonamides, amlodipine or other dihydropyridines, or any of the other ingredients of this medicine (listed in section 6);
• if the patient has experienced symptoms such as wheezing, swelling of the face or tongue, intense itching, or severe rash during previous treatment with an ACE inhibitor, or if such symptoms have occurred in the patient or a family member in any other circumstances (a condition called angioedema);

such symptoms may occur at any time during treatment, and the patient should stop taking IPAM and consult a doctor immediately.

• if the patient has severe liver disease or a condition called hepatic encephalopathy (a brain disorder caused by liver disease);
• if the patient is suspected of having untreated or uncontrolled heart failure (severe water retention, breathing difficulties);
• if the patient is taking medicines that are not anti-arrhythmic, causing life-threatening irregular heartbeat (torsades de pointes);
• if the patient has a narrowing of the aortic valve in the heart (aortic stenosis) or cardiogenic shock (a condition in which the heart is unable to supply enough blood to the body);
• if the patient has heart failure after a heart attack;
• if the patient has very low blood pressure (hypotension);
• if the patient has low potassium levels in the blood;
• if the patient has severe kidney disease, which reduces blood flow to the kidneys (renal artery stenosis);
• if the patient is undergoing dialysis or blood filtration by other methods. Depending on the device used, IPAM may not be suitable for the patient;
• if the patient has moderate kidney disease (applies to IPAM 10 mg + 2.5 mg + 5 mg and 10 mg + 2.5 mg + 10 mg);
• after the third month of pregnancy (it is also recommended to avoid taking IPAM in early pregnancy - see the section on pregnancy);
• if the patient has diabetes or kidney problems and is being treated with a blood pressure lowering medicine containing aliskiren;
• if the patient has taken or is currently taking a combination medicine containing sacubitril and valsartan, used to treat chronic heart failure, as the risk of angioedema (rapid swelling of tissues under the skin in the throat area) increases (see "Warnings and precautions" and "IPAM and other medicines").

Warnings and precautions

If any of the following conditions apply to the patient, they should consult a doctor or pharmacist before taking IPAM:

• if the patient has hypertrophic cardiomyopathy (a heart muscle disease) or renal artery stenosis (narrowing of the blood vessel supplying the kidney);
• if the patient has heart failure or any other heart disease;
• if the patient has a significant increase in blood pressure (hypertensive crisis);
• if the patient has liver disease;
• if the patient has collagenosis (a disease of the connective tissue), such as systemic lupus erythematosus or scleroderma;
• if the patient has atherosclerosis (hardening of the arteries);
• if the patient is undergoing parathyroid function tests;
• if the patient has gout;
• if the patient has diabetes;
• if the patient is on a low-salt diet or uses salt substitutes containing potassium (it is essential to maintain proper potassium levels in the blood);
• if the patient is taking lithium or potassium-sparing diuretics (spironolactone, triamterene), as their use with IPAM should be avoided (see "IPAM and other medicines");
• if the patient is elderly and the dose needs to be increased;
• if the patient has had allergic reactions to sunlight;
• in black patients, angioedema (swelling of the face, lips, mouth, tongue, or throat, which can cause difficulty swallowing or breathing) may occur more frequently, and the medicine may be less effective in lowering blood pressure;
• if the patient is undergoing dialysis using high-flux membranes;
• if the patient has kidney disease or is on dialysis;
• if the patient experiences vision loss or eye pain. These may be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or increased pressure in the eye, which can occur within hours or weeks of taking IPAM. Untreated symptoms can lead to permanent vision loss. If the patient has previously been allergic to penicillin or sulfonamides, the risk of these disorders is higher.

The doctor may recommend regular monitoring of kidney function, blood pressure, and electrolyte levels (e.g., potassium) in the blood.
See also the subsection "When not to take IPAM".
The doctor may recommend blood tests to assess whether there has been a decrease in sodium or potassium levels or an increase in calcium levels in the blood.
The patient should inform the doctor about pregnancy, planned pregnancy, or suspected pregnancy. It is not recommended to take IPAM during early pregnancy and it should not be taken after the third month of pregnancy, as it may seriously harm the fetus (see the section on "Pregnancy and breastfeeding").
When taking IPAM, the patient should inform the doctor or medical staff if:

• the patient is to undergo anesthesia and/or surgery;
• the patient has recently experienced diarrhea or vomiting, or is dehydrated;
• the patient is to undergo LDL apheresis (mechanical removal of cholesterol from the blood);
• the patient is to undergo desensitization treatment to reduce allergic reactions after a bee or wasp sting;
• the patient is to undergo a test that requires the administration of a contrast agent containing iodine (a substance that allows organs such as the kidney or stomach to be seen on an X-ray).

Athletes should be aware that IPAM contains the active substance indapamide, which may cause a positive doping test result.

Children and adolescents

IPAM should not be given to children and adolescents.

IPAM and other medicines

The patient should tell the doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Patients with diabetes or kidney disease should not take aliskiren (used to treat high blood pressure).
The patient should avoid taking IPAM with:

• lithium (used to treat certain mental illnesses, such as mania, manic-depressive illness, and recurrent depression);
• potassium-sparing medicines (e.g., triamterene, amiloride), potassium supplements, or salt substitutes containing potassium, and other medicines that may increase potassium levels in the body (such as heparin, a medicine used to thin the blood and prevent clotting; trimethoprim and cotrimoxazole, also known as a combination medicine containing trimethoprim and sulfamethoxazole, used to treat bacterial infections);
• dantrolene (given by infusion), also used to treat malignant hyperthermia (a condition characterized by very high fever and muscle stiffness) during anesthesia;
• estramustine (used to treat cancer);
• medicines used to treat diarrhea (e.g., racecadotril) or medicines used to prevent the rejection of transplanted organs (e.g., sirolimus, everolimus, temsirolimus, and other medicines belonging to the group of so-called mTOR inhibitors). See the section "Warnings and precautions".
• a combination medicine containing sacubitril and valsartan (used to treat chronic heart failure). See the sections "When not to take IPAM" and "Warnings and precautions".
• other medicines used to treat high blood pressure: ACE inhibitors and angiotensin II receptor antagonists.

Taking other medicines may affect treatment with IPAM. The doctor may recommend a dose change and/or take other precautions. The patient should tell the doctor if they are taking any of the following medicines, as this may require special precautions:

• other medicines used to treat high blood pressure, including angiotensin II receptor antagonists (AIIRAs), aliskiren (see also the subsections "When not to take IPAM" and "Warnings and precautions"), or diuretics (medicines that increase urine production);
• potassium-sparing medicines used to treat heart failure: eplerenone and spironolactone in doses of 12.5 mg to 50 mg per day;
• anesthetics;
• iodine-containing contrast agents;
• bepridil (used to treat angina pectoris);
• methadone (used to treat addiction);
• medicines used to treat heart rhythm disorders (e.g., dofetilide, ibutilide, bretylium, cyzaprid, difemanil, procainamide, quinidine, hydroquinidine, disopyramide, amiodarone, sotalol);
• verapamil, diltiazem (used to treat heart conditions);
• digoxin or other cardiac glycosides (used to treat heart conditions);
• antibiotics used to treat bacterial infections (e.g., rifampicin, erythromycin, clarithromycin, sparfloxacin, moxifloxacin);
• antifungal medicines (e.g., itraconazole, ketoconazole, amphotericin B given by infusion);
• allopurinol (used to treat gout);
• antihistamines used to treat allergic reactions, such as hay fever (e.g., mizolastine, terfenadine, or astemizole);
• corticosteroids used to treat various diseases, including severe asthma and rheumatoid arthritis, as well as non-steroidal anti-inflammatory drugs (e.g., ibuprofen) or high doses of salicylates (e.g., acetylsalicylic acid, a substance found in many medicines, used as a pain reliever and to reduce fever, as well as to prevent blood clots);
• immunosuppressive medicines (given to control the immune system's response) used to treat autoimmune diseases or after organ transplantation (e.g., cyclosporine, tacrolimus);
• tetracosactide (used to treat Crohn's disease);
• gold salts, especially those given intravenously (used to treat symptoms of rheumatoid arthritis);
• halofantrine (used to treat certain types of malaria);
• baclofen (used to treat muscle stiffness in diseases such as multiple sclerosis);
• medicines used to treat diabetes, such as insulin or metformin;
• calcium, including calcium supplements;
• laxatives with a stimulating effect (e.g., senna);
• medicines used to treat cancer;
• vinpocetine (used to treat cognitive disorders in the elderly, including memory loss);
• medicines used to treat mental disorders, such as depression, anxiety, schizophrenia (e.g., tricyclic antidepressants, antipsychotic medicines, antidepressant medicines of the imipramine type, neuroleptics (e.g., amisulpride, sulpiride, sultopride, tiapride, haloperidol, droperidol));
• pentamidine (used to treat pneumonia);
• ritonavir, indinavir, nelfinavir (so-called protease inhibitors used to treat HIV infections);
• Hypericum perforatum(St. John's Wort);
• trimethoprim (used to treat infections);
• medicines used to treat low blood pressure, shock, or asthma (e.g., ephedrine, noradrenaline, or adrenaline);
• nitroglycerin and other nitrates or other vasodilators, as they may further lower blood pressure.

IPAM with food and drink

While taking IPAM, the patient should not consume grapefruits or grapefruit juice, as this may increase the levels of the active substance amlodipine, leading to an unexpected increase in the blood pressure lowering effect of IPAM.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult a doctor or pharmacist before taking this medicine.

Pregnancy

The patient should inform the doctor about pregnancy, suspected pregnancy, or planned pregnancy.
Normally, the doctor will advise the patient to stop taking IPAM before planned pregnancy or as soon as pregnancy is confirmed, and will recommend an alternative medicine. It is not recommended to take IPAM during early pregnancy, and it should not be taken after the third month of pregnancy, as it may seriously harm the fetus.

Breastfeeding

The patient should inform the doctor if they are breastfeeding or plan to breastfeed. It is not recommended to take IPAM while breastfeeding, especially when breastfeeding a newborn or premature baby. The doctor may recommend an alternative medicine.

Driving and using machines

IPAM may affect the patient's ability to drive or operate machines. If taking IPAM causes nausea, dizziness, fatigue, or headache, the patient should not drive or operate machines and should contact their doctor immediately.

IPAM contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which means it is essentially "sodium-free".

3. How to take IPAM

This medicine should always be taken exactly as prescribed by the doctor or pharmacist. If the patient has any doubts, they should consult their doctor or pharmacist.
The tablet should be swallowed with a glass of water, preferably in the morning, before breakfast. The doctor will determine the appropriate dose for the patient. The recommended dose is usually one tablet per day.

Taking a higher dose of IPAM than recommended

Taking too many tablets may cause blood pressure to drop, even to a dangerous level, which may be accompanied by symptoms such as nausea, vomiting, cramps, dizziness, drowsiness, disorientation, and decreased urine production or absence of urine production. The patient may feel "lightheaded" or weak. If blood pressure drops significantly, shock may occur, characterized by cold and moist skin, and the patient may lose consciousness. Even 24-48 hours after taking the medicine, shortness of breath due to excess fluid accumulation in the lungs (pulmonary edema) may occur.
If the patient has taken too many IPAM tablets, they should contact their doctor or go to the emergency department of the nearest hospital immediately.

Missing a dose of IPAM

It is essential to take the medicine every day, as regular treatment ensures more effective action. However, if a dose of IPAM is missed, the next dose should be taken at the usual time. The patient should not take a double dose to make up for the missed dose.

Stopping treatment with IPAM

Treatment for high blood pressure is usually long-term, so before stopping IPAM, the patient should consult their doctor.
If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.

4. Possible side effects

Like all medicines, IPAM can cause side effects, although not everyone gets them.

If the patient experiences any of the following serious side effects, they should stop taking IPAM and contact their doctor immediately:

• sudden onset of wheezing, chest pain, shortness of breath, or difficulty breathing (not very common - may occur in less than 1 in 100 patients);
• swelling of the eyelids, face, or lips (not very common - may occur in less than 1 in 100 patients);
• swelling of the mucous membrane of the mouth, tongue, or throat, causing significant difficulty breathing (not very common - may occur in less than 1 in 100 patients);
• severe skin reactions, including severe rash, hives, redness of the skin all over the body, intense itching, blistering, peeling, and swelling of the skin, and inflammation of the mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis) or other allergic reactions (very rare - may occur in less than 1 in 10,000 patients);
• severe dizziness or fainting (common - may occur in less than 1 in 10 patients);
• heart attack (very rare - may occur in less than 1 in 10,000 patients), life-threatening heart rhythm disorders (frequency not known);
• pancreatitis, which can cause severe abdominal pain, radiating to the back, and very poor general condition (very rare - may occur in less than 1 in 10,000 patients);
• muscle weakness, cramps, tenderness, or pain, especially if the patient feels unwell or has a high temperature, which may be caused by abnormal muscle breakdown (frequency not known).

Side effects, grouped by frequency of occurrence:

• Very common(occurring in at least 1 in 10 patients): Edema (fluid retention).
• Common(occurring in less than 1 in 10 patients): Low potassium levels in the blood, headache, dizziness of central origin, palpitations (feeling of heartbeat), sudden flushing of the face and neck, dizziness of labyrinthine origin, feeling of tingling or numbness, vision disturbances, double vision, tinnitus (feeling of hearing sounds), feeling of "emptiness" in the head due to low blood pressure, cough, shortness of breath, gastrointestinal disorders (nausea, vomiting, abdominal pain, taste disturbances, indigestion or digestive disorders, diarrhea, constipation, changes in bowel movements), allergic reactions (such as rash, itching), muscle cramps, feeling of tiredness, weakness, drowsiness, swelling of the ankles.
• Uncommon(occurring in less than 1 in 100 patients): Mood changes, anxiety, depression, sleep disturbances, tremors, hives, fainting, numbness, irregular or rapid heartbeat, inflammation of the nasal mucosa (swelling or discharge from the nose), hair loss, purpura (red spots on the skin), skin discoloration, itching, sweating, chest pain, muscle or joint pain, back pain, pain, poor general condition, kidney disorders, urinary disorders, need to urinate at night, increased frequency of urination, impotence (inability to achieve or maintain an erection), fever or elevated body temperature, discomfort or enlargement of the breasts in men, weight gain or loss, increased white blood cell count, hyperglycemia (very high blood sugar levels), low sodium levels in the blood, which may cause dehydration and low blood pressure, vasculitis (inflammation of blood vessels), photosensitivity reaction (changes in skin appearance) after exposure to sunlight or artificial UVA rays, blistering skin lesions, swelling of the hands or feet, increased creatinine and urea levels in the blood, falls, dryness of the mucous membrane of the mouth.
• Rare(occurring in less than 1 in 1,000 patients): Disorientation, abnormal laboratory test results: low chloride levels in the blood, low magnesium levels in the blood, increased liver enzyme activity, high bilirubin levels in the serum; exacerbation of lupus erythematosus (a type of collagenosis). Abnormal electrocardiogram (ECG) recording; in the case of systemic lupus erythematosus, symptoms may worsen. Myopia, blurred vision, decreased vision, or eye pain due to high pressure (possible symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma). Tremors, stiffness, mask-like face, slow movements, and shuffling gait. Cyanosis, numbness, and pain in the fingers of the hands or feet (Raynaud's phenomenon).
• Very rare(occurring in less than 1 in 10,000 patients): Decreased white blood cell count, decreased platelet count (which can cause easy bruising and bleeding from the nose), anemia (decreased red blood cell count), angina pectoris (chest pain, jaw pain, and back pain caused by exertion and related to heart disease), eosinophilic pneumonia (a rare type of pneumonia), gingival hyperplasia (gum overgrowth), severe skin reactions, including severe rash, redness of the skin all over the body, intense itching, blistering, peeling, and swelling of the skin, and inflammation of the mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis), erythema multiforme (rash, often starting with red, itchy patches on the face, arms, or legs), bleeding, tender, or swollen gums, liver function disorders, hepatitis, severe kidney function disorders, jaundice (yellowing of the skin), abdominal distension (gastritis), nerve disorders that can cause weakness, tingling, or numbness, increased muscle tone, hyperglycemia (very high blood sugar levels), high calcium levels in the blood, stroke, likely secondary to significant blood pressure lowering, hepatic encephalopathy (a brain disorder caused by liver disease); abnormal ECG recording; in the case of systemic lupus erythematosus, symptoms may worsen. Myopia, blurred vision, decreased vision, or eye pain due to high pressure (possible symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma).
• Frequency not known(cannot be estimated from available data): Hepatic encephalopathy (a brain disorder caused by liver disease), abnormal ECG recording. In the case of systemic lupus erythematosus, symptoms may worsen. Myopia, blurred vision, decreased vision, or eye pain due to high pressure (possible symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma). Tremors, stiffness, mask-like face, slow movements, and shuffling gait. Cyanosis, numbness, and pain in the fingers of the hands or feet (Raynaud's phenomenon).

Changes in laboratory test results (blood tests) may occur. The doctor may recommend blood tests to monitor the patient's health.
If any of these symptoms occur, the patient should contact their doctor as soon as possible.

Reporting side effects

If the patient experiences any side effects, including those not listed in this leaflet, they should inform their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of this medicine.

5. How to store IPAM

The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister after EXP. The expiry date refers to the last day of the month.
There are no special storage instructions for the medicine. Store in the original packaging to protect from light and moisture.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the pack and other information

What IPAM contains

• The active substances of IPAM are: perindopril arginine, indapamide, and amlodipine. Each film-coated tablet of IPAM 5 mg + 1.25 mg + 5 mg contains 5 mg of perindopril arginine, equivalent to 3.395 mg of perindopril, 1.25 mg of indapamide, and 5 mg of amlodipine (as amlodipine besylate). Each film-coated tablet of IPAM 5 mg + 1.25 mg + 10 mg contains 5 mg of perindopril arginine, equivalent to 3.395 mg of perindopril, 1.25 mg of indapamide, and 10 mg of amlodipine (as amlodipine besylate). Each film-coated tablet of IPAM 10 mg + 2.5 mg + 5 mg contains 10 mg of perindopril arginine, equivalent to 6.79 mg of perindopril, 2.5 mg of indapamide, and 5 mg of amlodipine (as amlodipine besylate). Each film-coated tablet of IPAM 10 mg + 2.5 mg + 10 mg contains 10 mg of perindopril arginine, equivalent to 6.79 mg of perindopril, 2.5 mg of indapamide, and 10 mg of amlodipine (as amlodipine besylate).
• Other ingredients of the tablet are: microcrystalline cellulose, calcium carbonate, pregelatinized starch, sodium croscarmellose, magnesium stearate, and anhydrous colloidal silica. IPAM 5 mg + 1.25 mg + 5 mg and IPAM 10 mg + 2.5 mg + 10 mg: the coating contains copolymer of polyvinyl alcohol and polyethylene glycol, talc, titanium dioxide (E171), glycerol monocaprylocaprate, and polyvinyl alcohol. IPAM 5 mg + 1.25 mg + 10 mg and IPAM 10 mg + 2.5 mg + 5 mg: the coating contains copolymer of polyvinyl alcohol and polyethylene glycol, talc, titanium dioxide (E171), glycerol monocaprylate (type 1), polyvinyl alcohol, yellow iron oxide (E172), black iron oxide (E172), and red iron oxide (E172).

What IPAM looks like and contents of the pack

IPAM 5 mg + 1.25 mg + 5 mg: white, oval, film-coated tablets with "TEV" engraved on one side and "2" on the other side. The tablet dimensions are approximately 12.3 mm x 6.5 mm.
IPAM 5 mg + 1.25 mg + 10 mg: light beige, round, film-coated tablets with "TEV" engraved on one side and "3" on the other side. The tablet diameter is approximately 9.0 mm.
IPAM 10 mg + 2.5 mg + 5 mg: light beige, oval, film-coated tablets with "TEV" engraved on one side and "4" on the other side. The tablet dimensions are approximately 12.3 mm x 6.5 mm.
IPAM 10 mg + 2.5 mg + 10 mg: white, round, film-coated tablets with "TEV" engraved on one side and "5" on the other side. The tablet diameter is approximately 9.0 mm.
IPAM is available in blisters of 10, 30, 90, and 100 tablets, in a cardboard box.
Not all pack sizes may be marketed.

Marketing authorization holder

Teva B.V.
Swensweg 5
2031 GA, Haarlem
Netherlands

Manufacturer

Actavis Ltd.
BLB015, BLB016, Bulebel Industrial Estate
Zejtun ZTN3000
Malta
Teva Operations Poland Sp. z.o.o
ul. Mogilska 80
31-546 Kraków
To obtain further information, please contact the marketing authorization holder:
Teva Pharmaceuticals Polska Sp. z o.o., ul. Emilii Plater 53, 00-113 Warszawa, tel. (22) 345 93 00

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

Belgium

Perindopril/Indapamide/Amlodipine Teva Generics 5 mg/1.25 mg/5 mg filmomhulde tabletten/comprimés pelliculés/Filmtabletten
Perindopril/Indapamide/Amlodipine Teva Generics 5 mg/1.25 mg/10 mg filmomhulde tabletten/comprimés pelliculés/Filmtabletten
Perindopril/Indapamide/Amlodipine Teva Generics 10 mg/2.5 mg/5 mg filmomhulde tabletten/comprimés pelliculés/Filmtabletten
Perindopril/Indapamide/Amlodipine Teva Generics 10 mg/2.5 mg/10 mg filmomhulde tabletten/comprimés pelliculés/Filmtabletten

Bulgaria

Залпам Плюс 5 mg/1.25 mg/5 mg филмирани таблетки
Zalpam Plus 5 mg/1.25 mg/5 mg film-coated tablets
Залпам Плюс 5 mg/1.25 mg/10 mg филмирани таблетки
Zalpam Plus 5 mg/1.25 mg/10 mg film-coated tablets
Залпам Плюс 10 mg/2.5 mg/5 mg филмирани таблетки
Zalpam Plus 10 mg/2.5 mg/5 mg film-coated tablets
Залпам Плюс 10 mg/2.5 mg/10 mg филмирани Таблетки
Zalpam Plus 10 mg/2.5 mg/10 mg film-coated Tablets

Croatia

Perindopril arginin/Indapamid/Amlodipin Teva

Czech Republic

Articel Trio 5 mg/1,25 mg/5 mg filmom obložene tablete
Articel Trio 5 mg/1,25 mg/10 mg filmom obložene tablete
Articel Trio 10 mg/2,5 mg/5 mg filmom obložene tablete
Articel Trio 10 mg/2,5 mg/10 mg filmom obložene tablete

Estonia

Perindopril arginine/Indapamide/Amlodipine Teva 5 mg/1.25 mg/5 mg film-coated tablets
Perindopril arginine/Indapamide/Amlodipine Teva 5 mg/1.25 mg/10 mg film-coated tablets
Perindopril arginine/Indapamide/Amlodipine Teva 10 mg/2.5 mg/5 mg film-coated tablets
Perindopril arginine/Indapamide/Amlodipine Teva 10 mg/2.5 mg/10 mg film-coated tablets

Latvia

Perindopril arginine/Indapamide/Amlodipine Teva 5 mg/1.25 mg/5 mg apvalkotās tabletes
Perindopril arginine/Indapamide/Amlodipine Teva 5 mg/1.25 mg/10 mg apvalkotās tabletes
Perindopril arginine/Indapamide/Amlodipine Teva 10 mg/2.5 mg/5 mg apvalkotās tabletes
Perindopril arginine/Indapamide/Amlodipine Teva 10 mg/2.5 mg/10 mg apvalkotās tabletes

Lithuania

IPAM

Luxembourg

Perindopril + Indapamida + Amlodipina ratiopharm

Poland

Perindopril arginină/Indapamidă/Amlodipină Teva 5 mg/1,25 mg/5 mg comprimate filmate
Perindopril arginină/Indapamidă/Amlodipină Teva 5 mg/1,25 mg/10 mg comprimate filmate
Perindopril arginină/Indapamidă/Amlodipină Teva 10 mg/2,5 mg/5 mg comprimate filmate
Perindopril arginină/Indapamidă/Amlodipină Teva 10 mg/2,5 mg/10 mg comprimate filmate

Portugal

Perindopril arginín/indapamid/amlodipín Teva 5 mg/1,25 mg/5 mg
Perindopril arginín/indapamid/amlodipín Teva 5 mg/1,25 mg/10 mg
Perindopril arginín/indapamid/amlodipín Teva 10 mg/2,5 mg/5 mg Perindopril arginín/indapamid/amlodipín Teva 10 mg/2,5 mg/10 mg

Romania

PERINDOPRIL/INDAPAMIDE/AMLODIPINA TEVA

Slovakia

Perindopril arginine/Indapamide/Amlodipine Teva

Slovenia

Perindopril arginin/Indapamid/Amlodipin Teva

Spain

Perindopril/Indapamida/Amlodipino Teva

United Kingdom

Perindopril/Indapamide/Amlodipine Teva

Date of last revision of the leaflet:April 2025